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Staphylococcus aureus continues to be a major cause of
community-acquired and health-care related infections in the
United States and around the world (1,2). Approximately 20%
of community-acquired and nosocomial bacteremias in the
United States are caused by S. aureus (3-5). The emergence of
high levels of penicillin resistance followed by the
development and spread of strains resistant to the
semisynthetic penicillins (methicillin, nafcillin, and oxacil-
lin), macrolides, tetracyclines, and aminoglycosides has made
therapy of staphylococcal disease a global challenge (1,6,7). In
the 1980s, because of widespread occurrence of methicillin-
resistant S. aureus (MRSA), empiric therapy for staphylococ-
cal infections (particularly nosocomial sepsis) was changed to
vancomycin in many health-care institutions (8-12).
Vancomycin use in the United States also increased during
this period because of the growing numbers of infections with
Clostridium difficile and coagulase-negative staphylococci in
health-care facilities (8,9). Thus, the early 1990s saw a
discernible increase in vancomycin use. As a consequence,
selective pressure was established that  eventually led to the
emergence of strains of S. aureus and other species of
staphylococci with decreased susceptibility to vancomycin
and other glycopeptides.
In 1997, the first strain of S. aureus with reduced
susceptibility to vancomycin and teicoplanin was reported
from Japan (13). Shortly thereafter, two additional cases from
the United States were reported (14). While vancomycin
therapy appeared to have failed in the patients infected with
these organisms, debate was considerable about whether
such strains should be designated as resistant to
glycopeptides, since the levels of vancomycin required to
inhibit the growth of the strains remained low (vancomycin
MIC = 8 µg/mL). Three years later, the debate continues. At
the heart of the discussion are conflicting definitions of
resistance and resistance breakpoints, a handful of
nonstandardized laboratory methods, and a very small
sample size of strains collected from the far corners of the
world upon which to draw conclusions (15-17). We address
this question of reduced susceptibility versus resistance.
Reduced Susceptibility Versus Resistance—
Definitions and Interpretive Criteria
The National Committee for Clinical Laboratory
Standards (NCCLS) defines staphylococci requiring concen-
trations of vancomycin of <4 µg/mL for growth inhibition as
susceptible, those requiring 8 µg/mL to 16 µg/mL for
inhibition as intermediate, and those requiring concentra-
tions of > 32 µg/mL as resistant (18). Similarly, for teicoplanin
(a drug not approved for use in the United States),
staphylococci requiring inhibitory concentrations of <8 µg/mL
are designated as susceptible, those requiring 16 µg/mL for
inhibition as intermediate, and those requiring concentra-
tions of > 32 µg/mL as resistant. Thus, the acronyms VISA
(vancomycin-intermediate  S. aureus) and GISA (glycopep-
tide-intermediate  S. aureus) come directly from the
interpretive criteria published by NCCLS. While GISA is
technically a more accurate description of the strains isolated
to date, since most are classified as intermediate to both
vancomycin and teicoplanin, the term glycopeptide may not
be recognized by many clinicians. Thus, the term VISA, which
emphasizes a change in vancomycin MICs similar to
vancomycin-resistant enterococci (VRE), may be a more
effective way of communicating to clinicians the changes
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occurring in the susceptibility of staphylococci to vancomycin.
Although NCCLS has also defined disk-diffusion criteria for
interpretation of vancomycin results for staphylococci (19),
this method is not sufficiently sensitive to detect decreased
susceptibility to vancomycin in staphylococci and should not
be used for routine testing of staphylococci (19,20).
In the United States, the term vancomycin-resistant
S. aureus (VRSA) is reserved for S. aureus strains for which
the vancomycin or teicoplanin MICs are > 32 µg/mL, as is also
true in France, where the Comité de l’Antibiogramme de la
Société Française Microbiologie has published breakpoints
similar to those of NCCLS (21). However, using the
interpretive criteria of the British Society for Antimicrobial
Chemotherapy, strains for which the vancomycin MICs are
> 8 µg/mL would be reported as VRSA (22). Interpretive
criteria for vancomycin from these three organizations are
shown (Table 1).
The term VRSA also has been used by Japanese
investigators to denote strains of S. aureus that grow on a
brain heart infusion screening (BHI) agar plate containing
4 µg/mL of vancomycin within 24 hours, provided that the
vancomycin broth microdilution MIC is at least 8 µg/mL (23).
Those strains that produce colonies on vancomycin-
containing BHI agar with vancomycin MICS of < 4 µg/mL are
termed heteroresistant VRSA or hetero-VRSA. By population
analysis, subpopulations can be detected in hetero-VRSA
strains, often representing only 1 in 100,000 daughter cells,
for which the vancomycin MICs are 8 µg/mL. Such strains
were first reported from Japan in 1996 (13).  The prototype
strain is S. aureus Mu3, for which the vancomycin MIC range
(by standard broth microdilution testing) is 1 µg/mL to
2 µg/mL. Often the vancomycin MICs reported for hetero-
VRSA isolates in the literature are those obtained from
colonies preselected on vancomycin-containing media and are
not those of the original isolate. As Howe et al. point out, this
process may, in fact, be selecting for resistance in vitro rather
than screening for it (24). Whether the isolation of such
hetero-VRSA strains from patients explains the apparent
failure of vancomycin therapy remains controversial. While
some of the isolates, such as those from Hong Kong (25), have
been associated with therapeutic failures with vancomycin,
many hetero-VRSA strains (or hetero-VISA strains, as they
are also known) were detected through retrospective
laboratory screening of MRSA isolates, and the clinical
significance of the isolates is unknown (26-28).
Epidemiology of VRSA and VISA Strains
Strains of VISA (vancomycin MIC = 8 µg/mL) have been
reported from Japan (13), the United States (29-31), France
(32), United Kingdom (24), and Germany (26). Most of these
isolates appear to have developed from preexisting MRSA
infections. Hetero-VRSA strains have been reported from
Spain (33), Scotland (34), Hong Kong (25), Germany (26,28),
and Greece, among other countries (27). Most of these isolates
were detected during retrospective testing surveys using BHI
agar containing 4 µg/mL of vancomycin. For example, a
hetero-VRSA isolate from Egypt, first isolated in 1981, was
not identified until 1998 during a retrospective review of
MRSA strains by Bierbaum et al. (26).
Evidence from the few affected U.S. patients investigated
to date suggests that infections caused by VISA, for which the
vancomycin MICs are 8 µg/mL, are refractory to vancomycin
therapy (29). The Centers for Disease Control and Prevention
(CDC) has received reports of several other infections caused
by S. aureus for which the vancomycin MICs were 4 µg/mL,
which suggests that some of these patients did not improve on
appropriate vancomycin therapy. Data from rabbit endocardi-
tis models presented by Climo et al. (35) also suggest that
vancomycin monotherapy is not adequate for VISA strains.
However, the combination of oxacillin and vancomycin is
synergistic both in vitro and in vivo in the endocarditis model
(35). Similar data on the synergy of beta-lactams and
vancomycin for VISA strains were reported by Sieradzki et al.
(36). However, the accumulated experience from humans and
animals is too small for firm conclusions regarding a loss in
the effectiveness of vancomycin for such infections,
particularly those caused by strains of S. aureus that are
heteroresistant to glycopeptides. Our inability to differenti-
ate in the laboratory between vancomycin-susceptible
S. aureus strains (i.e., those for which the vancomycin MICs
are < 2 µg/mL) that have vancomycin-resistant subpopula-
tions versus those vancomycin-susceptible strains that do not
have such subpopulations hinders our efforts to clarify the
effectiveness of vancomycin for staphylococcal infections.
Mechanisms of Reduced
Susceptibility to Vancomycin
The mechanisms by which S. aureus isolates become
more resistant to vancomycin are poorly understood.
However, many of the clinical and laboratory-derived strains
with decreased susceptibility to vancomycin share unique
features. For example, most VISA strains for which the
vancomycin MICs are 8 µg/mL show longer doubling times,
decreased lysostaphin susceptibilities, and reduced autolytic
activity (37,38). Studies conducted at CDC with Mu50 and the
Michigan and the New Jersey VISA strains used changes in
redox potential over time as an indicator of bacterial growth
measured by using a Cytosensor Microphysiometer System
(Molecular Devices Corporation, Sunnyvale, CA). These
studies showed dramatically longer doubling times for the
VISA strains (Figure 1, three curves on right) compared with
the methicillin- and vancomycin-susceptible control strain S.
aureus ATCC 25923 and two MRSA control strains obtained
from CDC (3 curves on left side of Figure 1). However, several
authors have noted that the vancomycin MICs for VISA
strains are not stable and decrease over time in the absence of
selective pressure (35,37,38).
Hanaki et al. reported that hetero-VRSA produced three-
to five-fold greater quantities of penicillin-binding proteins 2
and 2' and increased quantities of cell-wall precursors, which
presumably trap vancomycin extracellularly (39). In addition,
amidation of glutamine residues in cell-wall muropeptides
has been reported, which presumably reduces the cross-linking
Table 1. Examples of vancomycin interpretive criteria used
internationally
   Interpretive criteria for vancomycin (µg/mL)
Organizationa Susceptible Intermediate Resistant
NCCLS <4 8-16 >32
CA-SFM <4 8-16 >32
BSAC <4 ------   >8
aNCCLS, National Committee for Clinical Laboratory Standards;
CA-SFM, Comité de l’Antibiogramme de la Société Française
Microbiologie; BSAC, British Society for Antimicrobial Chemo-
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within the cell walls, thereby also reducing the number of
intracellular vancomycin target molecules (40). Geisel et al.
reported similar biochemical changes in seven MRSA isolates
with reduced susceptibility to vancomycin (hetero-VISA)
isolated from patients from three hospitals in Düsseldorf,
Germany (28). Two of the patients had received vancomycin
before the hetero-VISA strains were isolated. All seven
isolates, obtained in 1998, had identical pulsed-field gel
electrophoresis profiles identical to that of the northern
Germany epidemic strain. Whether heteroresistance is a
characteristic of all the progeny of this clone is unknown.
Laboratory Detection of VISA
 Most VISA isolates initially appear mixed, demonstrat-
ing two distinct colony types; however, both colony types yield
identical antimicrobial susceptibility test results (Figure 2).
Decreased susceptibility to vancomycin (i.e., an MIC of
vancomycin of 8 µg/mL) was detected in the S. aureus isolates
from Michigan and New Jersey by broth microdilution when
incubated for 24 hours at 35°C (20). On the other hand, the
isolate from New York often demonstrated a vancomycin MIC
of 4 µg/mL by broth microdilution but an MIC of 6 µg/mL by
Etest methods. Thus, a single MIC test method may not be
accurate enough to detect all VISA strains. CDC has adopted
three criteria to identify VISA strains (Table 2), broth
microdilution vancomycin MICs of 8-16 µg/mL, Etest (AB
Biodisk, Piscataway, NJ) vancomycin MICs of >6 µg/mL, and
growth on commercial BHI agar screen plates containing
6 µg/mL of vancomycin within 24 hours.
VISA isolates are not reliably distinguished from
vancomycin-susceptible isolates by the rapid automated
methods, such as MicroScan (Dade MicroScan, West
Sacramento, CA) rapid panels (20). NCCLS disk-diffusion
method and the Stokes method are not accurate predictors of
reduced vancomycin susceptibility in staphylococci (20,41).
Recent changes in Vitek (Biomérieux, Hazelwood, MO)
software (version 7.01) may have improved VISA detection
(CDC, unpub. obs.).
The clinical significance of heteroresistance is an issue of
considerable controversy regarding the emergence of
decreased susceptibility of staphylococci to vancomycin.
Staphylococcal isolates with vancomycin MICs of 1 µg/mL
to 4 µg/mL can be heterogeneous, that is, only small
subpopulations of the isolates will grow in the presence of
vancomycin concentrations of 8 µg/mL to 16 µg/mL, often 1
daughter cell in 105 CFU. Identifying isolates with
subpopulations demonstrating heterogeneous resistance to
vancomycin is difficult. CDC has chosen to use an inoculum of
106 CFU/mL on BHI containing 6 µg/mL of vancomycin for
screening. All the isolates for which the vancomycin MICs are
8 µg/mL grow on these screening plates. Mu3, the hetero-
VRSA strain from Japan, does not grow on this medium (20).
Hiramatsu et al. (23) suggest using an inoculum of 108 CFU/
mL on BHI agar containing 4 µg/mL of vancomycin and cell-
wall precursors (called Mu3 supplement) to screen for hetero-
VRSA. Others have used this approach, omitting the
Figure 1. Growth curves of Staphylococcus aureus strains measured
by changes in redox potential on a cytosensor. Starting from the far
right of the graph are the Michigan strain, the Japanese strain
Mu50, the New Jersey strain, and three vancomycin-susceptible
control strains.
Figure 2. A blood agar plate incubated for 24h at 35°C in which the
multiple colonial morphologies of the Michigan VISA strain can be
observed.  The large cream colored colonies and smaller gray colonies
demonstrated the same antibiogram (vancomycin MIC= 8 ug/ml) and
pulsed field gel electrophoresis profiles.
Table 2. Key techniques for recognizing glycopeptide-intermediate
Staphylococcus aureus strainsa
Technique          Results         Comment
Broth microdilutionb Vancomycin MIC = Hold test for
  8-16 µg/mL in   full 24 hours
  Mueller-Hinton
  broth
Brain heart infusion Growth in 24 hours One or more colonies
  agar containing   is a positive result;
  6 µg/mL of   use S. aureus
  vancomycin   ATCC 25923 as
  obtained from a   negative control,
  commercial sourcec   and Enterococcus
  faecalis ATCC51299
  as positive control
Etest Vancomycin MIC Hold test for full 24
  >6 µg/mL on   hours
  Mueller-Hinton agar
aAll three criteria must be met before an organism is defined as a
glycopeptide-intermediate S. aureus.
bCDC uses inhouse-prepared MIC plates; however, any full dilution
range broth microdilution plates, such as MicroScan conventional
panels or PASCO frozen MIC panels, if incubated at 35°C for a full 24
hours, can be used.
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supplements (26). Bierbaum et al. reported that 23 of 25
isolates showing growth on BHI agar containing 4 µg/ml of
vancomycin were classified as susceptible by NCCLS criteria
(vancomycin MICs < 4 µg/mL) even after growth on agar
containing 4 µg/mL vancomycin. For the remaining two
isolates, the vancomycin MICs were 8 µg/mL; however, the
inoculum for the test was taken from vancomycin-containing
agar. In our experience (42), growth of a variety of S. aureus
isolates on screening plates with concentrations of 4 µg/mL of
vancomycin is not unusual, but rarely do such strains have
elevated vancomycin MICs. Thus, the clinical significance of
such isolates remains unclear. Until further clinical data are
available to assess the significance of heteroresistance,
routine screening of S. aureus isolates for vancomycin-
heteroresistant subpopulations is not warranted in the
United States. Such screening may be undertaken as part of
research protocols, but results generated using screening
agars with low concentrations of vancomycin, the Etest
method with a high inoculum (108 CFU/mL) on BHI agar with
prolonged incubation, or vancomycin high-salt agar should
not be reported as VRSA on a patient’s medical record.
 Surveillance for VISA
A recent survey of laboratories participating in CDC’s
Emerging Infections Program indicated that many are not
using methods that can detect VISA strains (43). Yet, it is
crucial that laboratories develop an algorithm for identifying
VISA in their institutions if our understanding of how to treat
these infections is to improve. Screening all isolates of
S. aureus is neither cost-effective nor prudent at this time,
given the low prevalence of such strains. Rather, focusing
screening efforts on MRSA isolates is likely to be more
successful since most VISA and hetero-VRSA isolates to date
have been MRSA. With regard to surveillance of patient
populations, hemodialysis and chronic ambulatory peritoneal
dialysis patients are known to be at high risk for developing
MRSA infections since they frequently are carriers of MRSA
(44) and often receive long-term glycopeptide therapy. Such
patients may be monitored for emerging VISA infections as
should other patients who are predisposed to MRSA
infections and receive vancomycin.
Infection Control Issues
The most prudent approach to curtailing the spread of
VISA infections is still a matter of opinion. CDC has issued
interim guidelines to aid hospitals in establishing programs
for control of staphylococci with reduced susceptibility to
vancomycin (45), and CDC’s Hospital Infection Control
Practices Advisory Committee has published guidelines for
prudent vancomycin use (46). Others have suggested
alternative approaches (47). The transfer of VISA strains
beyond the source patient has not been documented in the
United States, perhaps because the patients reported in
Michigan and New Jersey were already in isolation because of
pre-existing MRSA or vancomycin-resistant enterococcal
infections (29). Identification of a VISA infection in a health-
care setting should prompt a careful epidemiologic
investigation. Since MRSA are known to be highly
transmissible in health-care settings, it is reasonable to
assume that VISA isolates would be no less transmissible
given the opportunity.
Alternative Therapies
The antibiograms of U.S., German, and French VISA
isolates  (Table 3) show that isolates remained susceptible to
at least some common antimicrobial agents, such as
trimethoprim-sulfamethoxazole, as well as to newer agents,
such as linezolid and quinupristin-dalfopristin (20). However,
the possibility that newer VISA isolates will be resistant to all
common drugs in addition to glycopeptides has to be
considered. Several of the patients with VISA isolates from
Japan and the United States responded to alternate therapies
that included arbikacin and ampicillin-sulbactam, gentami-
cin, and trimethoprim-sulfamethoxazole. Whether the next
VISA isolate will have a more resistant antibiogram is a
matter of considerable speculation.
Future Trends
To date, staphylococci harboring the vancomycin
resistance genes from enterococci have not been isolated from
clinical samples, although some investigators have specifi-
cally looked for them (20,38,48). However, isolates of
staphylococci appear to have achieved clinically relevant
levels of resistance that lead to treatment failures even
without the vancomycin resistance genes from enterococci.
While CDC recommends that enhanced infection control
efforts be initiated for S. aureus isolates for which the
vancomycin MICs are 8 µg/mL (45), the need for such
precautions for strains with MICs of 4 µg/mL is under debate.
Such strains of staphylococci, including species other than
S. aureus (49,50), will continue to emerge, particularly in
patients who receive long-term vancomycin therapy. Thus,
efforts to contain VISA infections before they become truly
resistant to all available antimicrobial agents should be an
infection control priority.
Table 3. Resistance patterns of staphylococcal study isolates to
commonly tested antimicrobial agentsa
   Resistant or
Isolate (source)   intermediateb     Susceptible
Staphylococcus aureus Cd, Cip, E, Gm, C, L, Q-D, Rif,
  (Michigan)   Ox, P   SXT, T
S. aureus (New Jersey) Cd, Cip, E, Ox, C, Gm, L, Q-D,
  P, Rif   SXT, T
S. aureus (New York) Cip, E, Ox, P, Rif C, Cd, Gm, L, Q-D,
  SXT, T
S. aureus (Illinois) C(I), Cd, Cip, E, L, Q-D, SXT, T
  Ox, P, Rif
S. aureus (Germany) Ak, Cd, Cip, E, Fu, Ne
  Gm, Ox, P, Te
S. aureus C, Cd, Cip, E, Ox, C, L, Q-D, SXT
  (France, LIM-2)   P, Rif, Te
aAs determined using the broth microdilution reference method.
bAbbreviations: C: chloramphenicol; Cd: clindamycin; Cip:
ciprofloxacin; E: erythromycin; Fu, fusidic acid; Gm: gentamicin; L:
linezolid; Ne: netilmycin; Ox: oxacillin; P: penicillin; Q-D,
quinupristin-dalfopristin; Rif: rifampin; SXT: trimethoprim/
sulfamethoxazole; T: tetracycline. (I): intermediate. Based on data
presented in references 20, 26, 32, and unpublished observations
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